This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about ATTR-CM and uncover the differences between hereditary and Wild-type ATTR-CM

Learn about the red flags that may raise suspicion of and techniques used to diagnose ATTR-CM

Explore a range of educational resources to support the diagnosis of ATTR-CM

Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

What is Transthyretin Amyloid Cardiomyopathy (ATTR-CM)?

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rare, and ultimately fatal disease, characterised by the deposition of amyloid fibrils in the myocardium, leading to heart failure. There could be one patient in every heart failure clinic.1,2,3

Building the knowledge: Biological foundations of ATTR amyloidosis

This is a series of animated, educational modules that outline key background information on ATTR amyloidosis. This video reviews the biological foundation and disease mechanism of ATTR amyloidosis.

Symptoms onset typically over the age of 50-60 years and include:4,5
​​​​​​

  • ​​​​​​​​​​​​​​​​​​​​​shortness of breath​​​​​​​
  • cardiac arrhythmias, particularly atrial fibrillation​​​​​​
  • heart failure
  • oedema​​​​​​
  • fatigue
  • orthostasis
  • angina

Cardiac signs include arrhythmias, thickening of the ventricular walls and interventricular septum, as well as cardiomyopathy, resulting in heart failure.5

The disease results in considerable physical and emotional impact for patients and their carers across multiple domains.​6
In the UK there is a delay to diagnosis (>4 years in 42% of cases of wild-type ATTR-CM). Barriers to diagnosis are thought to be a major reason for shortened survival with patients using hospital services a median (interquartile range) of 17 (9–27) times during the 3 years before diagnosis; by which time physical function and quality of life is greatly depleted.2

At this point, the prognosis of patients with ATTR-CM is poor; median survival in the UK varies between 2 and 5.5 years.2,7,8

The prognosis worsens with continued amyloid deposits, therefore early diagnosis is key to improving patient outcomes.1,7​​​​​​​

Explore more

Different Types of ATTR-CM

Learn more

See other educational resources available

Explore more


References:
  1. Witteles RM, Bokhari S, Damy T et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019; 7(8): 709–716
  2. Lane T, Fontana M, Martinez-Naharro A et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019; 140: 16–26.
  3. Pfizer Data on File PP-VYN-GBR-0145 2020
  4. Ruberg FL and Berk JL. Transthyretin (TTR) Cardiac Amyloidosis. Circulation. 2012; 126: 1286–1300.
  5. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018; 33(5): 571–579.
  6. Stewart M, Shaffer S, Murphy B et al. Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers. Neurol Ther. 2018; 7: 349–364.
  7. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017; 135(14): 1357–1377.
  8. Grogan M, Scott CG, Kyle RA, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016; 68(10): 1014–1020.
PP-VYN-GBR-0240. June 2021

Quick Links

View a range of educational resources to support the diagnosis of ATTR-CM

Listen to our faculty of expert speakers and download resources including our interactive ATTR-CM Red Flags guide. You can also access and sign up to upcoming virtual events. 

PP-VYN-GBR-0729. May 2021

Explore Educational Resources

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. October 2020

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No